Sign in
CompletedPhase 2

Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Albuquerque, Conroe, and Houston, United StatesSee the 4 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
35 people, planned
Started
8 Aug 2016
Ended
19 Apr 2024
Type of study
Interventional
Treatments tested
  • Frameless Fractionated Stereotactic Radiation Therapy
Record updated
23 April 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • All patients with 1-4 metastatic brain lesions who are considered eligible for single-fraction, frame-based SRS, who are unable or unwilling to undergo frame-based SRS
  • One to 4 untreated metastatic brain lesions
  • Each brain lesion must be less than or equal to 5 cm in diameter and not an optimal surgical candidate
  • Patient must be able have a magnetic resonance imaging (MRI) of the brain for treatment planning
  • Histologic confirmation of malignancy
  • For patients of childbearing potential, non-pregnant state, confirmed by negative serum or urine beta-human chorionic gonadotropin (HCG) within (7) days of planned radiation treatment
  • Glomerular filtration rate (GFR) adequate for intravenous (IV) contrast delivery for imaging
  • No concurrent chemotherapy
  • Patient may have had prior therapy for brain metastasis, including radiosurgery and surgical resection at the discretion of the treating physician however only new untreated lesions will be followed on protocol

Who cannot take part

  • Patients willing to be treated with frame-based gamma knife SRS at MD Anderson main campus or MD Anderson at the Woodlands
  • Primary small cell lung cancer, myeloma, lymphoma, leukemia, or other histologies not optimally treated with SRS
  • Patients currently receiving chemotherapy/biologic/immunotherapy as these need to be held during FFSRT
  • Prior whole brain radiotherapy or conventional external beam radiotherapy
  • Positive pregnant status confirmed by serum or urine pregnancy test
  • Five or more metastatic brain lesions
  • Brain lesion(s) greater than 5 cm in diameter
  • Lesion(s) involving the brainstem, optic chiasm or optic nerve(s)
  • Patients unable to have IV contrast for computed tomography (CT) and MRI imaging
  • Patient unable to have an MRI of the brain

Where in United States

  • Presbyterian HospitalAlbuquerque, United States
  • MD Anderson in The WoodlandsConroe, United States
  • M D Anderson Cancer CenterHouston, United States
  • MD Anderson West HoustonHouston, United States

About the trial

What the trial wants to find out

This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly to the brain lesions while sparing normal tissues.

The group in the trial

  • Treatment (FFSRT)Treatment being tested

    Patients undergo FFSRT daily over 30 minutes for 3-5 days.

    Treatment: Frameless Fractionated Stereotactic Radiation Therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study of the Efficacy, Safety, and Cost of Frameless Fractionated Stereotactic Radiation for Parenchymal Brain Metastases
Record updated
23 April 2024